Original from: 360dx

Artificial intelligence firm Stratipath announced Monday that it has entered into a nonexclusive collaboration with Roche to distribute Stratipath's breast cancer risk stratification digital pathology solution.

Under the deal, Roche customers will be able to access Stratipath Breast through Roche's Navify Digital Pathology platform. CE-marked Stratipath Breast uses deep learning and artificial intelligence to analyze digitized hematoxylin- and eosin-stained histopathology images of breast cancer tissue to identify patients with increased risk of disease progression, Stockholm-based Stratipath said in a statement.

"By integrating with Roche’s Navify Digital Pathology enterprise software, a large number of pathology labs globally now gain rapid access to AI-based prognostic insights, all while streamlining laboratory processes and minimizing costs," Stratipath CEO and Cofounder Fredrik Wetterhall said.

In a separate announcement on Monday, Seoul-based artificial intelligence company Deep Bio also announced a collaboration with Roche to integrate its suite of AI-based algorithms into Navify. Deep Bio offers the DeepDx Prostate algorithm, which helps diagnose prostate cancer, enables gland-level Gleason grading, and provides tissue and tumor measurements.

Fellow South Korean digital pathology firm Lunit also on Monday announced that its Lunit SCOPE PD-L1 22C3 TPS algorithm for PD-L1 scoring has been integrated into Navify.

Financial and other terms of the deal were not disclosed.

Source: Roche, Stratipath Ink Deal to Distribute Breast Cancer Digital Pathology Solution